Brief: Nymox reports successful new phase 3 long-term Fexapotide repeat injection BPH trial results
11/10/2016 15:00
Oct 11 (Reuters) - Nymox Pharmaceutical Corp NYMX.O
* Nymox reports successful new phase 3 long-term fexapotide
repeat injection bph trial results: lasting symptomatic
improvement up to 6 years after single repeated treatment
* Nymox pharmaceutical - Results show there was long-term
statistically significant symptomatic improvement compared to
phase 3 patients who received placebo alone
Source text for Eikon: ID:nGNXNHYHWa
Further company coverage: NYMX.O
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Nymox Pharmaceutical
See all newsBrief: Nymox Says Required To Resubmit Application To DKMA
Brief: Nymox Pharmaceutical Corp Says Terminated Employment Of Christopher R Riley As CFO (June 27)
Brief: Nymox Announces Appointment Of Christopher R. Riley As Chief Financial Officer
Brief: Nymox Appeals Deficiency Letter
U.S. STOCKS ON THE MOVE-Pot stocks, Nymox, Zynerba